Skip to content

Transvaginal Natural Orifice Endoscopic Presacral–Uterosacral Ligament Compound Suspension for the Treatment of Middle Pelvic Organ Prolapse: A Multicenter Prospective Single-Arm Study

Transvaginal Natural Orifice Endoscopic Presacral–Uterosacral Ligament Compound Suspension for the Treatment of Middle Pelvic Organ Prolapse: A Multicenter Prospective Single-Arm Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400090097
Enrollment
Unknown
Registered
2024-09-24
Start date
2024-09-30
Completion date
Unknown
Last updated
2024-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pelvic organ prolapse

Interventions

Test group:Transvaginal Natural Orifice Endoscopic Presacral–Uterosacral Ligament Compound Suspension

Sponsors

Obstetrics and Gynecology Hospital of Fudan University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Patients who have completed childbirth and have no further desire for fertility. 2. Patients who refuse conservative treatment or for whom conservative treatment has failed. 3. Patients who are willing to undergo surgery and are undergoing pelvic organ prolapse surgery for the first time. 4. Patients with stage II or higher uterine prolapse based on POP-Q scoring, primarily with middle compartment prolapse within the hymenal ring, and possibly with other site prolapses. 5. Patients may have concurrent urinary incontinence. 6. Patients who are willing to comply with regular follow-up after surgery.

Exclusion criteria

Exclusion criteria: 1. Patients with a subjective desire to reject this surgical procedure. 2. Patients with a history of previous pelvic prolapse surgery. 3. Patients with a history of uterine hysterectomy. 4. Patients with a strong desire to preserve the uterus. 5. Patients with severe medical or surgical conditions, tumors, infections, or bleeding disorders that make them unsuitable for surgery. 6. Patients suspected of or diagnosed with malignant pelvic tumors.

Design outcomes

Primary

MeasureTime frame
Surgical success outcomes;

Secondary

MeasureTime frame
Primary perioperative evaluation indicators;Functional outcomes;postoperative complications;

Countries

China

Contacts

Public ContactYisong Chen

Obstetrics and Gynecology Hospital of Fudan University

cys373900207@163.com+86 136 0191 3713

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026